Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 2018 Advances for Practitioners

    Contains 5 Component(s) Recorded On: 11/12/2018

    AASLD's Advances for Practitioners presented at The Liver Meeting® 2018.

    This program reviews the most recent advances in the clinical management of patients with cirrhosis. Topics of discussion include the use of beta blockers, anticoagulants and albumin for managing different complications of cirrhosis. Additionally, the most updated recommendations regarding  screening issues for patients with cirrhosis will be reviewed.

    Michael B. Fallon

    Juan G. Abraldes

    Guadalupe Garcia-Tsao

    Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

    Nicolas M. Intagliata

  • Clinical Practice SIG: Best Practices in Hepatology 2018

    Contains 8 Component(s) Recorded On: 11/12/2018

    AASLD's Clinical Practice SIG presented at The Liver Meeting® 2018.

    This program aims to help attendees understand how to best approach the patient referred for evaluation of an incidentally found liver mass, be better informed on how to conduct office-based noninvasive assessment of liver fibrosis in the patient with elevated liver tests, increase their understanding of the management of alcoholic liver disease in 2018 and have the knowledge to provide care in the post-liver transplant patient in the community setting.

    K. Rajender Reddy

    Marcelo Kugelmas

    Craig J. McClain

    Kirti Shetty

  • Diversity Workshop: Ethnic and Racial Disparities in Liver Diseases

    Product not yet rated Contains 7 Component(s) Recorded On: 11/12/2018

    AASLD's Diversity Workshop presented at The Liver Meeting® 2018.

    This session will describe the biological and social determinants of health that contribute to ethnic and racial disparities in health and health care; identify the racial and ethnic disparities that have been documented in patients with primary HCC and liver transplantation; and list strategies to prevent viral hepatitis, reduce deaths and decrease health disparities due to HBV and HCV in the U.S.

    Stephen Thomas

    Fasiha Kanwal

    Kimberly A. Forde

    Andrew J. Muir

    Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.

  • 2018 Global Forum: Global Challenges in HCC Risk and Surveillance

    Contains 8 Component(s) Recorded On: 11/12/2018

    AASLD's Global Forum presented at The Liver Meeting® 2018.

    HCC is the fifth most common cancer and the third cause of cancer-related deaths worldwide. The underlying liver disease that ultimately leads to HCC varies throughout the world. Identifying the population at risk for HCC is critical in order to implement preventive strategies to reduce the burden of the disease. Moreover, identifying the population at risk will facilitate the use of surveillance programs. This forum will review, in all pertinent regions of the world, the main populations at risk for HCC and discuss strategies for reducing the burden of the disease through prevention and surveillance.

    Hashem B. El-Serag

    Jordi Bruix

    Diana A. Payawal

    Flair Jose Carrilho

    Edith Okeke

  • AASLD/ALEH Joint Symposium

    Product not yet rated Contains 8 Component(s) Recorded On: 11/11/2018

    AASLD/ALEH Joint Symposium presented at The Liver Meeting® 2018.

    The goal of this program is to highlight the hepatic manifestations of various diseases endemic or epidemic in the Tropics. These diseases include viral A and E hepatitis; hepatic manifestations of viral epidemics like Dengue, SARS, and Zika virus; bacterial infections like typhoid; and parasitic diseases like malaria.

    Kenneth Sherman

    Harshad Devarbhavi

    Maria Cassia Mendes

    Edna Strauss

    Robert Gish

  • General Hepatology Update

    Contains 5 Component(s) Recorded On: 11/11/2018

    AASLD's General Hepatology Update presented at The Liver Meeting® 2018.

    This activity will provide updates and practical guidance for care providers dealing with 3 common and or difficult to manage conditions. The knowledge will improve practitioner's performance as care providers and will improve patient outcomes.

    Cynthia Levy

    Cynthia Levy, MD, FAASLD is currently a Professor of Medicine in the Division of Hepatology at the University of Miami Miller School of Medicine. Dr. Levy received her MD from Universidade Federal do Rio de Janeiro, Brazil. She completed an Internal Medicine residency at University of Miami, a Gastroenterology Fellowship at Mayo Clinic, Rochester, and a Transplant Hepatology Fellowship at University of Florida, Gainesville, having received an AASLD Fellowship Award. Dr. Levy is a member of the AASLD Practice Guidelines Committee and of the ABIM Test and Policy Committee on Transplant Hepatology.  At the University of Miami, Dr. Levy is the program director for the Transplant Hepatology Fellowship program and Associate Director for the Schiff Center for Liver Diseases, where she conducts several industry-sponsored and investigator-initiated studies for cholestatic and autoimmune liver diseases.

    Mina Rakoski

    Mina Rakoski is a Transplant Hepatologist at Loma Linda University Health. She completed her medical education at Jefferson Medical College in Philadelphia, her residency at Cedars-Sinai Medical Center in Los Angeles and her Gastroenterology and Transplant Hepatology Fellowships at University of Michigan in Ann Arbor. During her time at University of Michigan, she attained her Master of Science in Health and Health Care Research through the Rackham Graduate School.

    Dr. Rakoski has a clinical and research interest in palliative care for patients with cirrhosis and hepatocellular carcinoma. She has a dual appointment in both Gastroenterology as well as Palliative Care at Loma Linda. She has started a hepatology palliative care clinic where she is able to provide integrated hepatology and palliative care services including in-office therapeutic paracentesis for patients with advanced liver disease. She is a co-investigator on a multicenter study funded by Patient-Centered Outcomes Research Institute (PCORI), which is investigating a novel approach of integrating palliative care into subspecialty clinics. She has written several review articles on palliative care in liver disease as well as presented on this topic at national conferences.

    Kymberly Watt

  • Hepatitis B SIG: HBV Flares: Distinguishing the Good from the Bad

    Contains 10 Component(s) Recorded On: 11/11/2018

    AASLD'S Hepatitis B SIG: HBV Flares: Distinguishing the Good from the Bad presented at The Liver Meeting® 2018.

    Chronic HBV (CHB) infection follows a dynamic course with multiple phases of disease with various durations.  ALT flares during CHB can be challenging for clinicians to manage.  In some settings ALT flares herald a transition from active to inactive disease and thus are considered to be beneficial. In other scenarios, they may indicate aggressive inflammatory liver disease than can lead to progressive liver injury or even fulminant hepatic failure. Understanding and distinguishing these 'good' and 'bad' flares is not only a clinical challenge but a key to understanding the natural history and the therapeutic goals of HBV treatment. The program starts with a definition of flares and the current understanding of their immunological pathophysiology. Flares in different clinical settings will also be discussed (focusing on their beneficial and potentially harmful effects). Finally, attendees will hear about management strategies for ATL flares.  

    Marc G. Ghany

    Dr. Ghany is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 

     

    Kyong-Mi Chang

    Dr. Kyong-Mi Chang is an Associate Professor of Medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School of Medicine, with administrative leadership role as the Associate Chief of Staff and Associate Dean for Research at the Philadelphia Corporal Michael J. Crescenz VA Medical Center (CMC VAMC). Dr. Chang received her MD and Internal Medicine residency training from the Medical College of Pennsylvania, followed by clinical GI fellowship training at the University of California in San Diego, also receiving her postdoctoral research training at the Scripps Research Institute studying CTL escape in HCV persistence. She has been a faculty member in GI Division at the University of Pennsylvania School of Medicine and the CMC VAMC since 1999 with active clinical and research activities. Her translational research focuses on immune pathogenesis in human hepatitis C and B virus infection with and without HIV coinfection—including various immune regulatory mechanisms such as FoxP3+ Tregs, IL-10+ Tr1 cells, gdT-cells, PD-1 and CTLA-4. Dr. Chang is also participating in the Million Veteran Program—a multi-center VA genomic study. She is a Fellow of the American Association for Study of Liver Disease (FAASLD) and a member of the American Society for Clinical Investigation (ASCI).

    Henry Chan

    Harry Janssen

    Anna S. Lok

    Kumar Visvanathan

  • Hepatobiliary Neoplasia SIG: New Therapies in HCC: Mechanisms of Action and Indications

    Contains 7 Component(s) Recorded On: 11/11/2018

    AASLD's Hepatobiliary Neoplasia SIG: New Therapies in HCC: Mechanisms of Action and Indications presented at The Liver Meeting® 2018.

    This program will describe the molecular mechanisms and rationale for novel systemic therapy agents targeting signaling pathways and immune mechanisms that have been recently approved for the treatment of hepatocellular carcinoma. The program will also cover the roles of new agents in the current AASLD guidelines for treatment of hepatocellular carcinoma.

    Jessica Zucman-Rossi

    Augusto Villanueva

    Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York). He received his medical degree from the University of Santiago de Compostela (Spain), and he is board certified in Gastroenterology and Hepatology (Spain). In 2005, he joined the Division of Liver Diseases at Mount Sinai Hospital (New York) as a research fellow and was involved in different translational research projects focused on the molecular pathogenesis of hepatocellular carcinoma (HCC). In 2008, he obtained his PhD and received the Sheila Sherlock Fellowship from EASL to join the Liver Cancer Translational Research Laboratory of the BCLC Group, Barcelona (Spain). In 2010, he became the Scientific Manager of the HEPTROMIC consortium, a research initiative funded by the European Commission aimed at identifying genomic prognostic predictors and oncogenic drivers in HCC.

    In 2013, he joined the Institute of Liver Studies at King’s College (London), as a Senior Lecturer and Consultant Hepatologist where he served as co-leader of the HCC Clinic and Multidisciplinary Tumor Board. In 2014, he started his position at the Icahn School of Medicine at Mount Sinai with the goal of developing novel minimally invasive biomarkers using liquid biopsy and studying the impact of intratumor heterogeneity in HCC. He has more than 100 publications (10,000 citations, H-index 44) including articles in N Engl J MedNat GenetNat BiotechGastroenterology, HEPATOLOGY, J HepatolJ Clin InvestOncogene, etc. He wrote more than fifteen book chapters and edited a book on resistance to targeted therapies in HCC. He served as Associate Editor for J Hepatol (2014-2019) and Liver Cancer (2012-present).

    Josep Llovet

    Anthony El-Khoueiry

    Richard Finn

  • Hepatology Associates Course

    Product not yet rated Contains 12 Component(s) Recorded On: 11/11/2018

    AASLD's Hepatology Associates Course presented at The Liver Meeting® 2018.

    This half-day program provides an overview of both current and emerging therapies for common liver diseases. Additionally, it will enhance knowledge around diagnostics and highlight the roles of collaborating professionals.

    Yuko Kono

    John E. Eaton

    Dr. John Eaton is a transplant Hepatologist with a clinical and research focus on cholestatic liver diseases with an emphasis on primary sclerosing cholangitis (PSC) and related comorbid conditions. His clinical practice involves seeing a large volume of patients with PSC and PSC complicated by cholangiocarcinoma. Dr. Eaton’s research focus is the conduction of clinical trials and the discovery of novel biomarkers (including magnetic resonance imaging technologies) that can predict disease outcomes.

    Anne Croghan

    Robert S. Rahimi

    Romil Saxena

    Robert J. Fontana

    Jasmohan S. Bajaj

  • Hepatology Associates SIG: Avoiding Common Pitfalls in Cirrhosis Management

    Product not yet rated Contains 7 Component(s) Recorded On: 11/11/2018

    AASLD's Hepatology Associates SIG: Avoiding Common Pitfalls in Cirrhosis Management presented at The Liver Meeting® 2018.

    This program has been designed to improve the diagnosis, pharmacologic treatment and management of patients with chronic liver disease. The current data is highlighted to support effective and efficient patient-centered care. Attendees will gain the ability to utilize medical knowledge and research to provide quality, evidence-based care and to enhance interdisciplinary collaboration to improve health outcomes.

    Lisa M. Richards

    Tiffany E. Kaiser

    Carolyn J. Driscoll

    HoChong Gilles

    HoChong Gilles is a board-certified Nurse Practitioner and has been working in the hepatology field since 2001. She obtained a BS in Biology and Master’s in Nursing from Virginia Commonwealth University. She graduated with a Doctorate in Nursing Practice from the University of Virginia in 2018. Her research interests include portal hypertension and liver transplantation. She is the Clinical Program Manager for Hepatology and Liver Transplant at the McGuire Veterans Affairs Medical Center in Richmond, Virginia.

    Dr. Gilles is actively engaged in professional organizations including the American Association of the Study of Liver Diseases (AASLD). She was the immediate past Chair of the Hepatology Associates Committee is the Chair of the Hepatology Associates Special Interest Group. HoChong currently serves as the President of the Virginia Council of Nurse Practitioners.